Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

被引：44

作者：

Schoenfeld, Kurt ^{[1
]}

Zuber, Chantal ^{[1
]}

Pinkas, Jan ^{[2
]}

Haeder, Thomas ^{[1
]}

Bernoester, Katrin ^{[1
]}

Uherek, Christoph ^{[1
]}

机构：

[1] Biotest AG, Landsteinerstr 5, D-63303 Dreieich, Germany

[2] ImmunoGen Inc, 830 Winter St, Waltham, MA 02451 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2017年 / 10卷

关键词：

Multiple myeloma; Pre-clinical; Indatuximab ravtansine; Drug combination; Tumour regression; AGENTS;

D O I：

10.1186/s13045-016-0380-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/ dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.

引用

页数：4

共 50 条

[31] The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma
Cui, Yan
Turner, Joel G.
Dawson, Jana L.
Gomez, Juan A.
Shain, Kenneth H.
Meads, Mark B.
Baloglu, Erkan
Dalton, William S.
Nishihori, Taiga
Sullivan, Daniel M.
BLOOD, 2016, 128 (22)
[32] Targeted radiotherapy for patients with multiple myeloma: Results of pre-clinical evaluation of candidate antibodies.
Orchard, KH
Cooper, M
Mehta, A
Potter, M
Wijdenes, J
Borchardt, P
Quadri, S
Goldman, J
Samson, D
Apperley, J
Buscombe, J
Hilson, A
Myers, M
Amlot, P
Begent, R
Prentice, HG
BLOOD, 1999, 94 (10) : 302B - 302B
[33] Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities
Botta, Cirino
Gulla, Annemaria
Correale, Pierpaolo
Tagliaferri, Pierosandro
Tanssone, Pierfrancesco
FRONTIERS IN ONCOLOGY, 2014, 4
[34] Pre-clinical studies and evaluation of treatment need of glatiramer acetate depot
Bleich-Kimelman, N.
Rubnov, S.
Danon, U.
Marom, E.
Miller, A.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 688 - 688
[35] Preliminary pre-clinical studies on the side effects of breast cancer treatment
Salata, Camila
deAlmeida, Carlos E.
Ferreira-Machado, Samara C.
Barroso, Regina C.
Nogueira, Liebert P.
Mantuano, Andrea
Pickler, Arissa
Mota, Carla L.
de Andrade, Cherley B. V.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2021, 97 (07) : 877 - 887
[36] Pre-clinical studies of Gleevec and radiation in the treatment of mouse models of glioblastoma
Albert, JM
Shinohara, E
Geng, L
Tan, J
Osusky, K
Hallahan, D
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S259 - S260
[37] Cell Therapy for the Treatment of Neuropathic Pain: Pre-Clinical Studies to Evaluate Clinical Use
Wolfe, Stacey C. Quintero
Eaton, Mary
JOURNAL OF NEUROSURGERY, 2009, 111 (02) : 415 - 415
[38] Synaptic Dysfunction in Schizophrenia and the Effects of Treatment: Complementary in Vivo Clinical and Pre-clinical Studies
Howes, Oliver
Onwordi, Ellis
Whitehurst, Thomas
Shatalina, Ekaterina
Halff, Elise
Natesan, Sridhar
Vernon, Anthony
BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S34 - S35
[39] The cholinergic approach for the treatment of vascular dementia: Evidence from pre-clinical and clinical studies
Amenta, F
Di Tullio, MA
Tomassoni, D
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2002, 24 (7-8) : 697 - 713
[40] PRE-CLINICAL STUDIES INTO SYNCHRONIZATION OF OVULATION IN GILTS FOLLOWING TREATMENT WITH SUISYNCHRON, PMSG, AND HCG-GN-RH COMBINATION
BERGFELD, J
BRUSSOW, KP
MONATSHEFTE FUR VETERINARMEDIZIN, 1979, 34 (16): : 613 - 615

← 1 2 3 4 5 →